Moffitt Cancer Center Expands AI-Driven Immunotherapy Collaboration

Sign outside Moffitt Cancer Center in Tampa, Florida, one of the world’s leading National Cancer Institute-designated Comprehensive Cancer Centers.

Moffitt Cancer Center, Florida’s premier National Cancer Institute-designated facility, has expanded its partnership with biotechnology firm RyboDyn, Inc. to accelerate the development of advanced immunotherapies. The collaboration focuses on a newly identified class of tumor-specific proteins—known as Dark Targets™—discovered through RyboDyn’s proprietary AI-driven platform.

These novel proteins are invisible to standard detection methods and have been consistently observed in cancerous tissues, but not in healthy ones—making them strong candidates for more precise, less toxic cancer treatments. By leveraging Moffitt’s world-class tumor bank—one of the most comprehensive in the world—the partnership aims to validate these targets across a broad spectrum of cancers.

This research underscores the value of Florida’s continued investment in excellence. The state currently provides $127.5 million annually to support its four National Cancer Institute-designated research and treatment centers—ensuring they can attract top-tier talent and remain at the forefront of lifesaving innovation.

With its commitment to cutting-edge science and patient-centered care, Moffitt continues to set the standard for cancer research not just in Florida, but globally.